FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2756032213> ?p ?o ?g. }

• W2756032213 abstract "Background Patients (pts) with PsA experience significant impairment of work productivity (WP) and health-related QoL (HRQoL). Secukinumab (SEC) has previously been shown to rapidly improve symptoms, physical function and HRQoL in pts with active PsA. 1,2 Objectives To assess the impact of SEC on WP and HRQoL through 2 years (yrs) in TNF inhibitor (TNF)-naive PsA pts and those with an inadequate response or intolerance to TNF inhibitors (TNF-IR). Methods 606 and 397 pts were randomized to SEC or placebo (PBO) in FUTURE 1 (10 mg/kg IV followed by 150 or 75 mg SC) and FUTURE 2 (300, 150 or 75 mg SC), respectively. PBO pts were re-randomized to SEC at Wk 16/24. WP was assessed using the WP and Activity Impairment–General Health (WPAI-GH) questionnaire. WPAI-GH includes 6 questions to measure absenteeism, presenteeism, work productivity and impairments in unpaid activity because of health problems during the preceding 7 days. HRQoL was assessed using the PsAQoL questionnaire, encompassing 20 statements that pts rate as true or false on the day of completion. Across both trials, approximately 68% of pts were TNF-naive and 32% were TNF-IR. Observed data are presented from the full analysis set and in subgroups stratified by prior TNF exposure. Only data with approved doses of SEC (300 and 150 mg) are shown. Results In FUTURE 1, 88 of 202 in the SEC 150 mg group were employed and working at baseline (BL); 61 of 100 and 59 of 100 were employed and working at BL in the SEC 300 mg and 150 mg groups of FUTURE 2, respectively. Improvements in all elements of WPAI were reported with SEC 300 and 150 mg in the overall population at Wk 16; responses were sustained through Wk 104 (Table). The greatest improvements were seen in presenteeism (–10.0), work productivity (–10.3) and activity impairment (–14.1), which corresponded to improvements from BL of approximately 29%, 26% and 30%, respectively in the overall population of FUTURE 1 at Wk 104; similar improvements were seen in FUTURE 2 at Wk 104 (300 mg: –14.4 [42%], –11.2 [33%] and –17.7 [38%]; 150 mg: –16.8 [50%], –16.8 [45%] and –18.5 [38%]). Sustained improvements in all elements of WPAI were also evident with SEC in TNF-naive and TNF-IR pts in both FUTURE 1 and FUTURE 2. Improvements in PsAQoL were reported as early as Wk 4 and sustained through Wk 104. At Wk 104 of FUTURE 2, PsAQoL scores had improved by approximately 46% from BL with SEC 300 mg and 49% with SEC 150 mg in the overall population. Similar improvements were seen in TNF-naive (47% and 51%, respectively) and TNF-IR pts (45% and 45%, respectively). Consistent results were reported in FUTURE 1. The efficacy of SEC was consistent regardless of concomitant MTX use. Conclusions SEC provided sustained improvements in WP and PsAQoL in pts with PsA for up to 104 wks, regardless of prior TNF exposure. References McInnes. Lancet 2015;386:1137–46. Mease. NEJM 2015;373:1329–39. Disclosure of Interest V. Strand Consultant for: AbbVie, Amgen, BMS, Celgene, Celltrion, CORRONA, Genentech/Roche, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sanofi, and UCB, O. FitzGerald Grant/research support from: Abbvie, BMS, Celgene, Janssen, MSD, Novartis, Pfizer, Sun Pharma, UCB, L. Coates Grant/research support from: Abbvie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Sun Pharma, UCB, J. Walsh Consultant for: Novartis, J. Canete Consultant for: AbbVie, Boehringer Ingelheim, Celgene, Janssen, Lilly, Novartis, V. Bhosekar Employee of: Novartis, L. Pricop Employee of: Novartis, K. Gandhi Shareholder of: Novartis, Employee of: Novartis, S. Jugl Shareholder of: Novartis, Employee of: Novartis" @default.
• W2756032213 created "2017-09-25" @default.
• W2756032213 creator A5012283576 @default.
• W2756032213 creator A5035079125 @default.
• W2756032213 creator A5040724750 @default.
• W2756032213 creator A5077643606 @default.
• W2756032213 creator A5079883250 @default.
• W2756032213 creator A5083463038 @default.
• W2756032213 creator A5084523108 @default.
• W2756032213 creator A5086429582 @default.
• W2756032213 creator A5087919112 @default.
• W2756032213 date "2017-06-01" @default.
• W2756032213 modified "2023-10-10" @default.
• W2756032213 title "FRI0521 Secukinumab provides sustained improvements in work productivity and health related quality of life in patients with active psoriatic arthritis: 2-year results from future 1 and future 2" @default.
• W2756032213 doi "https://doi.org/10.1136/annrheumdis-2017-eular.1832" @default.
• W2756032213 hasPublicationYear "2017" @default.
• W2756032213 type Work @default.
• W2756032213 sameAs 2756032213 @default.
• W2756032213 citedByCount "1" @default.
• W2756032213 countsByYear W27560322132018 @default.
• W2756032213 crossrefType "proceedings-article" @default.
• W2756032213 hasAuthorship W2756032213A5012283576 @default.
• W2756032213 hasAuthorship W2756032213A5035079125 @default.
• W2756032213 hasAuthorship W2756032213A5040724750 @default.
• W2756032213 hasAuthorship W2756032213A5077643606 @default.
• W2756032213 hasAuthorship W2756032213A5079883250 @default.
• W2756032213 hasAuthorship W2756032213A5083463038 @default.
• W2756032213 hasAuthorship W2756032213A5084523108 @default.
• W2756032213 hasAuthorship W2756032213A5086429582 @default.
• W2756032213 hasAuthorship W2756032213A5087919112 @default.
• W2756032213 hasBestOaLocation W27560322131 @default.
• W2756032213 hasConcept C126322002 @default.
• W2756032213 hasConcept C139719470 @default.
• W2756032213 hasConcept C142724271 @default.
• W2756032213 hasConcept C159110408 @default.
• W2756032213 hasConcept C162324750 @default.
• W2756032213 hasConcept C168563851 @default.
• W2756032213 hasConcept C1862650 @default.
• W2756032213 hasConcept C187736073 @default.
• W2756032213 hasConcept C204787440 @default.
• W2756032213 hasConcept C204983608 @default.
• W2756032213 hasConcept C27081682 @default.
• W2756032213 hasConcept C27400517 @default.
• W2756032213 hasConcept C2776237627 @default.
• W2756032213 hasConcept C2776260265 @default.
• W2756032213 hasConcept C2777077863 @default.
• W2756032213 hasConcept C2779134260 @default.
• W2756032213 hasConcept C2779382274 @default.
• W2756032213 hasConcept C2779786854 @default.
• W2756032213 hasConcept C2779951463 @default.
• W2756032213 hasConcept C2992962319 @default.
• W2756032213 hasConcept C3019006561 @default.
• W2756032213 hasConcept C71924100 @default.
• W2756032213 hasConceptScore W2756032213C126322002 @default.
• W2756032213 hasConceptScore W2756032213C139719470 @default.
• W2756032213 hasConceptScore W2756032213C142724271 @default.
• W2756032213 hasConceptScore W2756032213C159110408 @default.
• W2756032213 hasConceptScore W2756032213C162324750 @default.
• W2756032213 hasConceptScore W2756032213C168563851 @default.
• W2756032213 hasConceptScore W2756032213C1862650 @default.
• W2756032213 hasConceptScore W2756032213C187736073 @default.
• W2756032213 hasConceptScore W2756032213C204787440 @default.
• W2756032213 hasConceptScore W2756032213C204983608 @default.
• W2756032213 hasConceptScore W2756032213C27081682 @default.
• W2756032213 hasConceptScore W2756032213C27400517 @default.
• W2756032213 hasConceptScore W2756032213C2776237627 @default.
• W2756032213 hasConceptScore W2756032213C2776260265 @default.
• W2756032213 hasConceptScore W2756032213C2777077863 @default.
• W2756032213 hasConceptScore W2756032213C2779134260 @default.
• W2756032213 hasConceptScore W2756032213C2779382274 @default.
• W2756032213 hasConceptScore W2756032213C2779786854 @default.
• W2756032213 hasConceptScore W2756032213C2779951463 @default.
• W2756032213 hasConceptScore W2756032213C2992962319 @default.
• W2756032213 hasConceptScore W2756032213C3019006561 @default.
• W2756032213 hasConceptScore W2756032213C71924100 @default.
• W2756032213 hasLocation W27560322131 @default.
• W2756032213 hasOpenAccess W2756032213 @default.
• W2756032213 hasPrimaryLocation W27560322131 @default.
• W2756032213 isParatext "false" @default.
• W2756032213 isRetracted "false" @default.
• W2756032213 magId "2756032213" @default.
• W2756032213 workType "article" @default.